STOCK TITAN
  1. Home
  2. Sec-filings
  3. RXRX
  4. [144] RECURSION PHARMACEUTICALS, INC. SEC Filing

Recursion Pharmaceuticals (RXRX) insider files to sell 100,000 Class A shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Christopher C. Gibson and related entities filed a notice to sell 100,000 Class A shares of Recursion Pharmaceuticals (RXRX) through Fidelity Brokerage Services, with an aggregate value of $326,754.06, on or after August 10, 2026 on NASDAQ.

The filing also lists extensive Class A share sales over the prior three months by Gibson, the Gibson Family Trust, and Lahwran-3 LLC, reflecting multiple transactions ranging from 40,000 to over 340,000 shares per trade.

Positive

  • None.

Negative

  • None.
Proposed shares to be sold 100000 shares Class A shares proposed for sale on or after August 10, 2026
Aggregate value of proposed sale $326,754.06 Total value for 100,000 Class A shares in proposed transaction
Acquisition date of founders shares 04/20/2021 Founders Shares acquired from issuer as compensation
Sale on 06/18/2026 340,440 shares for $1,089,541.29 Class A sale by Christopher C. Gibson
Sale on 07/07/2026 by Gibson Family Trust 50,000 shares for $195,014.41 Class A sale by Gibson Family Trust
Sale on 07/09/2026 by Lahwran-3 LLC 186,000 shares for $706,094.96 Class A sale by Lahwran-3 LLC
Form 144 regulatory
"144: Securities To Be Sold"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
Founders Shares financial
"Founders Shares | Issuer | | | 100000 | 04/20/2021 | Compensation"
Founders shares are a special block of a company’s stock originally given to the people who started the business; they often carry extra voting power or favorable terms compared with regular shares. For investors, these shares matter because they concentrate control and influence how future funding, ownership dilution, and decision-making will play out—think of founders shares as the steering wheel that can steer a company’s direction even as more passengers (investors) climb aboard.
compensation financial
"04/20/2021 | Founders Shares | Issuer | | | 100000 | 04/20/2021 | Compensation"
Gibson Family Trust financial
"Gibson Family Trust 41 S Rio Grande Street Salt Lake City UT 84101 | Class A"
Lahwran-3 Llc financial
"Lahwran-3 Llc 41 S Rio Grande Street Salt Lake City UT 84101 | Class A"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

FAQ

What does the RXRX Form 144 filed by Christopher C. Gibson disclose?
The Form 144 discloses a planned sale of 100,000 Class A shares of Recursion Pharmaceuticals through Fidelity Brokerage Services, with an aggregate value of $326,754.06, expected to be sold on or after August 10, 2026 on NASDAQ.

How many RXRX shares are proposed to be sold under this Form 144?
The filing covers a proposed sale of 100,000 Class A shares of Recursion Pharmaceuticals. These shares are identified as Founders Shares acquired on April 20, 2021 as compensation from the issuer.

What is the aggregate value of the planned RXRX share sale?
The planned sale of 100,000 Class A shares has an aggregate value of $326,754.06. This figure reflects the total dollar amount associated with the proposed transaction disclosed in the Form 144 filing.

Which brokerage and market are involved in the RXRX Form 144 sale?
The proposed RXRX share sale will be executed through Fidelity Brokerage Services LLC and is listed for trading on NASDAQ. The filing specifies Fidelity’s Smithfield, Rhode Island address as the brokerage’s location.

What prior RXRX share sales by Christopher C. Gibson are listed in the Form 144?
The filing lists multiple prior RXRX Class A sales in the last three months, including 340,440 shares for $1,089,541.29 on June 18, 2026 and several 100,000-share trades between late June and early August 2026.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR